Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 201–300 of 1,078

1. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
   Igor J. Puzanov, Mohammed M. Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael A. Chastain, Kevin S. Gorski, Abraham Anderson, Jeffrey Chou et al. · 2016 · Journal of Clinical Oncology
2. The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
   Hanke L. Matlung, Katka Szilagyi, Neil Barclay, Timo K. van den Berg · 2017 · Immunological Reviews
3. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
   Leisha A. Emens, Paolo A. Ascierto, Phillip Kevin Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco Maria Marincola · 2017 · European Journal of Cancer
4. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
   Cheng Xu, Yu‐Pei Chen, Xiao-Jing Du, Jin-Qi Liu, Cheng-Long Huang, Lei Chen, Guan‐Qun Zhou, Wen‐Fei Li, Yan‐Ping Mao, Chiun Hsu et al. · 2018 · BMJ
5. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
   De Martin, Eleonora, Michot, Jean-Marie, Papouin, Barbara, Champiat, Stéphane, Mateus, Christine, Lambotte, Olivier, Roche, Bruno, Antonini, Teresa Maria, Coilly, Audrey, Laghouati, Salim et al. · 2018 · Journal of Hepatology
6. CD4 and CD8 T lymphocyte interplay in controlling tumor growth
   Dmitrij Ostroumov, Nora Fekete-Drimusz, Michael Saborowski, Florian Kühnel, Norman Woller · 2017 · Cellular and Molecular Life Sciences
7. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
   Kurt Alex Schalper, Michael O. Carleton, Ming Zhou, Tian Chen, Ye Feng, Shu‐Pang Huang, Alice M. Walsh, Vipul A. Baxi, Dimple Pandya, Timothy C. Baradet et al. · 2020 · Nature Medicine
8. TIGIT predominantly regulates the immune response via regulatory T cells
   Sema Kurtuluş, Kaori Sakuishi, Shin Foong Ngiow, Nicole Joller, Dewar J. Tan, Michele W.L. Teng, Mark John Smyth, Vijay Kumar Kuchroo, Ana Carrizosa Anderson · 2015 · Journal of Clinical Investigation · Retracted
9. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
   Martin Reck, Alexander Valerievich Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-Long Lung Cancer Wu, Christoph Carl Zielinski, Michael Thomas et al. · 2016 · Journal of Clinical Oncology
10. Immune checkpoints and their inhibition in cancer and infectious diseases
    Lydia Dyck, Kingston H. G. Mills · 2017 · European Journal of Immunology
11. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
    Rozeman, Elisa A, Menzies, Alexander M, van Akkooi, Alexander C J, Adhikari, Chandra, Bierman, Carolien, van de Wiel, Bart A, Scolyer, Richard A, Krijgsman, Oscar, Sikorska, Karolina, Eriksson, Hanna et al. · 2019 · The Lancet Oncology
12. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
    Loi, Sherene, Dushyanthen, Sathana, Beavis, Paul A., Salgado, Roberto, Denkert, Carsten, Savas, Peter, Combs, Susan, Rimm, David L., Giltnane, Jennifer M., Estrada, Monica V. et al. · 2016 · Clinical Cancer Research
13. When worlds collide: Th17 and Treg cells in cancer and autoimmunity
    Knochelmann, Hannah M., Dwyer, Connor J., Bailey, Stefanie R., Amaya, Sierra M., Elston, Dirk M., Mazza-McCrann, Joni M., Paulos, Chrystal M. · 2018 · Cellular & Molecular Immunology
14. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
    Chao Wang, Wujin Sun, Yanqi Ye, Quanyin Hu, Hunter N. Bomba, Zhen Gu · 2017 · Nature Biomedical Engineering
15. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
    Adel Naimi, Rebar N. Mohammed, Ahmed Raji, Supat Chupradit, Alexei Valerievich Yumashev, Wanich Suksatan, Mohammed Nader Shalaby, Lakshmi Prasanth Thangavelu, Siavash Kamrava, Navid Shomali et al. · 2022 · Cell Communication and Signaling
16. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
    Bruce D. Cheson, Stephen Maxted Ansell, Larry Schwartz, Leo I. Gordon, Ranjana H. Advani, Heather A. Jacene, Axel Hoos, Sally Fiona Barrington, Philippe A. Armand · 2016 · Blood
17. The gut microbiota influences anticancer immunosurveillance and general health
    Routy, Bertrand, Gopalakrishnan, Vancheswaran, Daillère, Romain, Zitvogel, Laurence, Wargo, Jennifer A., Kroemer, Guido · 2018 · Nature Reviews Clinical Oncology
18. Application of PD-1 Blockade in Cancer Immunotherapy
    Xiaomo Wu, Zhongkai Gu, Chen Yang, Borui Chen, Wei Chen, Liqiang Weng, Xiaolong Liu · 2019 · Computational and Structural Biotechnology Journal
19. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
    Patrick Alexander Ott, Elena Élez, Sandrine Hiret, Dong‐Wan Kim, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Janice M. Mehnert · 2017 · Journal of Clinical Oncology
20. Immune suppressive mechanisms in the tumor microenvironment
    David H. Munn, Vincenzo Bronte · 2015 · Current Opinion in Immunology
21. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
    Kelly Dare Moynihan, Cary F. Opel, Gregory Lee Szeto, Alice Tzeng, Eric F. Zhu, J Engreitz, Robert T Williams, Kavya Rakhra, Michael H. Zhang, Adrienne M. Rothschilds et al. · 2016 · Nature Medicine
22. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
23. Novel patterns of response under immunotherapy
    Édith Borcoman, Yada Kanjanapan, Stéphane Champiat, Shotaro Kato, Vincent Servois, Razelle Kurzrock, Sanjay Goel, Philippe Lucien Bedard, Christophe Le Tourneau · 2019 · Annals of Oncology
24. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
    Jason J. Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion‐Sileni, Luis de la Cruz‐Merino, Muhammad A Khattak, Dirk Schadendorf, Georgina V Long et al. · 2022 · The Lancet
25. Roles of regulatory T cells in cancer immunity
    Yoshiko Takeuchi, Hiroyoshi Nishikawa · 2016 · International Immunology
26. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
    James Larkin, David R. Minor, Sandra P. D’Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald P. Linette, Bartosz Chmielowski, Christopher D. Lao et al. · 2017 · Journal of Clinical Oncology
27. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
    Coutzac, Clélia, Jouniaux, Jean-Mehdi, Paci, Angelo, Schmidt, Julien, Mallardo, Domenico, Seck, Atmane, Asvatourian, Vahe, Cassard, Lydie, Saulnier, Patrick, Lacroix, Ludovic et al. · 2020 · Nature Communications
28. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
    Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J. · 2016 · Journal for ImmunoTherapy of Cancer
29. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    Patrick Alexander Ott, Yung‐Jue Bang, Dominique Berton-Rigaud, Elena Élez, Michael Jon Pishvaian, Hope S. Rugo, Igor J. Puzanov, Janice M. Mehnert, Kyaw Lwin Aung, Juanita Suzanne Lopez et al. · 2017 · Journal of Clinical Oncology
30. Comprehensive analysis of the clinical immuno-oncology landscape
    Tang, J., Shalabi, A., Hubbard-Lucey, V.M. · 2018 · Annals of Oncology
31. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Adam Mackiewicz, Vanna Chiarion‐Sileni, Ana Maria Arance, Célèste Lebbé, Lars Bastholt, Omid Hamid, Piotr Lukasz Rutkowski et al. · 2017 · The Lancet Oncology
32. Cardiovascular toxicities associated with immune checkpoint inhibitors
    Hu, Jiun-Ruey, Florido, Roberta, Lipson, Evan J, Naidoo, Jarushka, Ardehali, Reza, Tocchetti, Carlo G, Lyon, Alexander R, Padera, Robert F, Johnson, Douglas B, Moslehi, Javid · 2019 · Cardiovascular Research
33. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
    on behalf of the Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, Frank Kroschinsky, Friedrich Stölzel, Simone von Bonin, Gernot Beutel, Matthias Kochanek, Michael G Kiehl, Peter Schellongowski · 2017 · Critical Care
34. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
    Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin Henner Voss, Padmanee Sharma, Sumanta Kumar Pal, Albiruni R. Abdul Razak et al. · 2017 · Journal of Clinical Oncology
35. Rational combinations of targeted cancer therapies: background, advances and challenges
    Jin, Haojie, Wang, Liqin, Bernards, René · 2023 · Nature Reviews Drug Discovery
36. Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
    Ashley V. Kroll, Ronnie H. Fang, Yao Jiang, Jiarong Zhou, Xiaoli Wei, Chun Lai Yu, Jie Gao, Brian T. Luk, Diana Dehaini, Weiwei Gao et al. · 2017 · Advanced Materials
37. PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
    Mizuki Nishino, Nikhil H. Ramaiya, Mark Magdi Awad, Lynette Marie Sholl, Jennifer A. Maattala, Myriam Taibi, Hiroto Hatabu, Patrick Alexander Ott, Philippe A. Armand, Frank Stephen Hodi · 2016 · Clinical Cancer Research
38. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
    Amber Jin Giles, Marsha-Kay N. D. Hutchinson, Heather M. Sonnemann, Jinkyu Jung, Peter Edward Fecci, Nivedita M. Ratnam, Wei Zhang, Hua Song, Rolanda Bailey, Dionne L. Davis et al. · 2018 · Journal for ImmunoTherapy of Cancer
39. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
    Capone, Mariaelena, Giannarelli, Diana, Mallardo, Domenico, Madonna, Gabriele, Festino, Lucia, Grimaldi, Antonio Maria, Vanella, Vito, Simeone, Ester, Paone, Miriam, Palmieri, Giuseppe et al. · 2018 · Journal for ImmunoTherapy of Cancer
40. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
    Margaret L. Axelrod, Rebecca S. Cook, Douglas Buckner Johnson, Justin Micah Balko · 2018 · Clinical Cancer Research
41. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
    Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami‐Chouaib · 2018 · Frontiers in Immunology
42. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
    Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández et al. · 2018 · Science Translational Medicine
43. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark Magdi Awad, Patrick Alexander Ott, Raphael Brandão Moreira, Fabio A.B. Schutz, Joaquim Bellmunt B, Guru Sonpavde, Frank Stephen Hodi et al. · 2017 · Cancer Immunology Research
44. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
    Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang et al. · 2018 · The Lancet Oncology
45. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review
    Abdel-Wahab, Noha, Shah, Mohsin, Lopez-Olivo, Maria A., Suarez-Almazor, Maria E. · 2018 · Annals of Internal Medicine
46. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
    Michael Orth, Philipp Metzger, Sabine Gerum, Julia V. Mayerle, Günter Schneider, Claus Belka, Maximilian Schnurr, Kirsten Lauber · 2019 · Radiation Oncology
47. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio, Vlahovic, Gordana, Lim, Michael, Sahebjam, Solmaz, Baehring, Joachim, Cloughesy, Timothy, Voloschin, Alfredo, Ramkissoon, Shakti H, Ligon, Keith L, Latek, Robert et al. · 2018 · Neuro-Oncology
48. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
    Luoma, Adrienne M., Suo, Shengbao, Williams, Hannah L., Sharova, Tatyana, Sullivan, Keri, Manos, Michael, Bowling, Peter, Hodi, F. Stephen, Rahma, Osama, Sullivan, Ryan J. et al. · 2020 · Cell
49. Cancer immunotherapies: advances and bottlenecks
    Rui, Rui, Zhou, Liqun, He, Shiming · 2023 · Frontiers in Immunology
50. PD-L1 Expression in Lung Cancer
    Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R. · 2016 · Journal of Thoracic Oncology
51. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
    Johnson, Douglas B., Frampton, Garrett M., Rioth, Matthew J., Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C., Fabrizio, David, Chalmers, Zachary R., Greenbowe, Joel et al. · 2016 · Cancer Immunology Research
52. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
    Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary Irvin Cohen, Thach‐Giao Truong, Helen Moon, Diwakar Davar, Mark Allen O’Rourke, Joseph J. Stephenson et al. · 2022 · Journal of Clinical Oncology
53. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
    Perez-Ruiz, Elisabeth, Minute, Luna, Otano, Itziar, Alvarez, Maite, Ochoa, Maria Carmen, Belsue, Virginia, de Andrea, Carlos, Rodriguez-Ruiz, Maria Esperanza, Perez-Gracia, Jose Luis, Marquez-Rodas, Ivan et al. · 2019 · Nature
54. Immune Checkpoint Inhibitors: Basics and Challenges
    Bin Li, Ho Lam Chan, Pingping Chen · 2017 · Current Medicinal Chemistry
55. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Pengfei Wang, Yang Chen, Siying Song, Tingjian Wang, Wenjun Ji, Shouwei Li, Ning Liu, Changxiang Yan · 2017 · Frontiers in Pharmacology
56. Role of PD-1 during effector CD8 T cell differentiation
    Eunseon Ahn, Koichi Araki, Masao Hashimoto, Weiyan Li, James L. Riley, Jeanne Cheung, Arlene H. Sharpe, Gordon James Freeman, Bryan A. Irving, Rafi Ahmed · 2018 · Proceedings of the National Academy of Sciences
57. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
    Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Herve R. Bonnefoi, Guy Jérusalem et al. · 2019 · The Lancet Oncology
58. Synthetic lethality as an engine for cancer drug target discovery
    Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber · 2019 · Nature Reviews Drug Discovery
59. Resistance Mechanisms to Anti-PD Cancer Immunotherapy
    Vesely, Matthew D., Zhang, Tianxiang, Chen, Lieping · 2022 · Annual Review of Immunology
60. Targeting T Cell Co-receptors for Cancer Therapy
    Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2016 · Immunity
61. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
    Jennifer E. Kim, Mira A. Patel, Antonella Mangraviti, Eileen S. Kim, Debebe Theodros, Esteban Velarde, Ann Liu, Eric W. Sankey, Ada J Tam, Haiying Xu et al. · 2016 · Clinical Cancer Research
62. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
    Lee, Karla A., Thomas, Andrew Maltez, Bolte, Laura A., Björk, Johannes R., de Ruijter, Laura Kist, Armanini, Federica, Asnicar, Francesco, Blanco-Miguez, Aitor, Board, Ruth, Calbet-Llopart, Neus et al. · 2022 · Nature Medicine
63. Role of tumor microenvironment in cancer progression and therapeutic strategy
    Qingjing Wang, Xueting Shao, Yuxuan Zhang, Miaojin Zhu, Frederick X.C. Wang, Jianjian Mu, Jiaxuan Li, Hangping Yao, Keda Chen · 2023 · Cancer Medicine
64. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
    Erkes, Dan A., Cai, Weijia, Sanchez, Ileine M., Purwin, Timothy J., Rogers, Corey, Field, Conroy O., Berger, Adam C., Hartsough, Edward J., Rodeck, Ulrich, Alnemri, Emad S. et al. · 2020 · Cancer Discovery
65. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Tuba Nur Gide, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long · 2017 · Clinical Cancer Research
66. Metabolic and epigenetic regulation of T-cell exhaustion
    Fabien Franco, Alison Jaccard, Pedro J. Romero, Yi-Ru Yu, Ping‐Chih Ho · 2020 · Nature Metabolism
67. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
    Oh, Min-Hee, Sun, Im-Hong, Zhao, Liang, Leone, Robert D., Sun, Im-Meng, Xu, Wei, Collins, Samuel L., Tam, Ada J., Blosser, Richard L., Patel, Chirag H. et al. · 2020 · Journal of Clinical Investigation
68. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
    Jeffrey E. Gershenwald, Richard A. Scolyer · 2018 · Annals of Surgical Oncology
69. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
    Richard D. Kim, Vincent M. Chung, Olatunji Boladale Alese, Bassel F. El‐Rayes, Daneng Li, Taymeyah Al‐Toubah, Michael J. Schell, Jun-Min Zhou, Amit Mahipal, Baek‐hui Kim et al. · 2020 · JAMA Oncology
70. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
    Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Michelle Medina, Harriet M. Kluger, Sajeve Samuel Thomas, Evidio Domingo‐Musibay, Anna C. Pavlick, Eric D. Whitman et al. · 2021 · Journal of Clinical Oncology
71. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
    Young Kwang Chae, Ayush Arya, Wade Thomas Iams, Marcelo Rocha de Souza Cruz, Sunandana Chandra, Jaehyuk Choi, Francis Joseph Giles · 2018 · Journal for ImmunoTherapy of Cancer
72. PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
73. Is autoimmunity the Achilles' heel of cancer immunotherapy?
    June, Carl H, Warshauer, Jeremy T, Bluestone, Jeffrey A · 2017 · Nature Medicine
74. Teaching an old dog new tricks: next-generation CAR T cells
    Nicholas J. A. Tokarew, Justyna Ogonek, Stefan Endres, Michael von Bergwelt‐Baildon, Sebastian Kobold · 2018 · British Journal of Cancer
75. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
    Schadendorf, Dirk, Wolchok, Jedd D., Hodi, F. Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher D., Chesney, Jason et al. · 2017 · Journal of Clinical Oncology
76. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
    Andrews, Miles C., Duong, Connie P. M., Gopalakrishnan, Vancheswaran, Iebba, Valerio, Chen, Wei-Shen, Derosa, Lisa, Khan, Md Abdul Wadud, Cogdill, Alexandria P., White, Michael G., Wong, Matthew C. et al. · 2021 · Nature Medicine
77. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Andrew Barker, William Edgar Carson, Carlo M. Contreras, Gregory A. Daniels, Dominick J. DiMaio, Ryan Courtney Fields, Martin D. Fleming et al. · 2019 · Journal of the National Comprehensive Cancer Network
78. CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
    Jarem J. Edwards, James S. Wilmott, Jason Madore, Tuba Nur Gide, Camelia Y. J. Quek, Annie T. Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey et al. · 2018 · Clinical Cancer Research
79. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
    Segal, Neil H., Logan, Theodore F., Hodi, F. Stephen, McDermott, David, Melero, Ignacio, Hamid, Omid, Schmidt, Henrik, Robert, Caroline, Chiarion-Sileni, Vanna, Ascierto, Paolo A. et al. · 2017 · Clinical Cancer Research
80. Early B cell changes predict autoimmunity following combination immune checkpoint blockade
    Das, Rituparna, Bar, Noffar, Ferreira, Michelle, Newman, Aaron M., Zhang, Lin, Bailur, Jithendra Kini, Bacchiocchi, Antonella, Kluger, Harriet, Wei, Wei, Halaban, Ruth et al. · 2018 · Journal of Clinical Investigation
81. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D. et al. · 2016 · European Journal of Cancer
82. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
    Frederick Arce Vargas, Andrew J.S. Furness, Isabelle Solomon, Kroopa Joshi, Leila Mekkaoui, Marta H. Lesko, Enrique Miranda, Rony Dahan, Andrew Georgiou, Anna Śledzińska et al. · 2017 · Immunity
83. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
    Nicholas A. Manieri, Eugene Y. Chiang, Jane L. Grogan · 2016 · Trends in Immunology
84. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
    Patrick J. Danaher, Sarah E. Warren, Rongze Olivia. Lu, Josue A. Samayoa, Amy H. Sullivan, Irena Pekker, Brett Wallden, Francesco Maria Marincola, Alessandra Cesano · 2018 · Journal for ImmunoTherapy of Cancer
85. Enhancing anti-tumour efficacy with immunotherapy combinations
    Funda Meric‐Bernstam, James Larkin, Josep M. Tabernero, Chiara Bonini · 2020 · The Lancet
86. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors
    Ford, Kirsty, Hanley, Christopher J., Mellone, Massimiliano, Szyndralewiez, Cedric, Heitz, Freddy, Wiesel, Philippe, Wood, Oliver, Machado, Maria, Lopez, Maria-Antoinette, Ganesan, Anusha-Preethi et al. · 2020 · Cancer Research
87. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
    Stephanie L. Goff, Mark E. Dudley, Deborah E. Citrin, Robert P. T. Somerville, John R. Wunderlich, David N. Danforth, Daniel A. Zlott, James Chih‐Hsin Yang, Richard Mark Sherry, Udai S. Kammula et al. · 2016 · Journal of Clinical Oncology
88. Emerging therapies for small cell lung cancer
    Sen Yang, Zhe Zhang, Qiming Wang · 2019 · Journal of Hematology & Oncology
89. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial
    Lebbé, Celeste, Meyer, Nicolas, Mortier, Laurent, Marquez-Rodas, Ivan, Robert, Caroline, Rutkowski, Piotr, Menzies, Alexander M., Eigentler, Thomas, Ascierto, Paolo A., Smylie, Michael et al. · 2019 · Journal of Clinical Oncology
90. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
    Cortazar, Frank B., Kibbelaar, Zoe A., Glezerman, Ilya G., Abudayyeh, Ala, Mamlouk, Omar, Motwani, Shveta S., Murakami, Naoka, Herrmann, Sandra M., Manohar, Sandhya, Shirali, Anushree C. et al. · 2020 · Journal of the American Society of Nephrology
91. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial
    Sharma, Padmanee, Pachynski, Russell K., Narayan, Vivek, Fléchon, Aude, Gravis, Gwenaelle, Galsky, Matthew D., Mahammedi, Hakim, Patnaik, Akash, Subudhi, Sumit K., Ciprotti, Marika et al. · 2020 · Cancer Cell
92. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
    Thomas Eigentler, Jessica C. Hassel, Carola Berking, Jens Aberle, Oliver P. Bachmann, Viktor Grünwald, Katharina Charlotte Kähler, Carmen Loquai, Niels Reinmuth, Martin B. Steins et al. · 2016 · Cancer Treatment Reviews
93. Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
    Laura C. Cappelli, Anna Kristina Gutierrez, Clifton O. Bingham, Ami A. Shah · 2016 · Arthritis Care & Research
94. Signal pathways of melanoma and targeted therapy
    Weinan Guo, Huina Wang, Chunying Li · 2021 · Signal Transduction and Targeted Therapy
95. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
    Stefani Spranger, Jason J. Luke, Riyue Bao, Yuanyuan Zha, Kyle M. Hernandez, Li Yan, Alexander P. Gajewski, Jorge Andrade, Thomas F. Gajewski · 2016 · Proceedings of the National Academy of Sciences
96. Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Theodore Scott Nowicki, Siwen Hu‐Lieskovan, Antoni Ribas · 2018 · The Cancer Journal
97. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
    Laura C. Cappelli, Anna Kristina Gutierrez, Alan N. Baer, Jemima Albayda, Rebecca Manno, Uzma Jalal Haque, Evan J. Lipson, Karen B. Bleich, Ami A. Shah, Jarushka Naidoo et al. · 2016 · Annals of the Rheumatic Diseases
98. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
    Maria Secrier, Xiaodun Li, Nadeera de Silva, Matthew Eldridge, Gianmarco Contino, Jan Bornschein, Shona MacRae, Nicola Grehan, Maria O’Donovan, Ahmad Miremadi et al. · 2016 · Nature Genetics
99. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
    Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. Van Beijnum B, Patrycja M. Nowak-Sliwinska, Arjan W. Griffioen · 2021 · Nature Reviews Clinical Oncology
100. Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
     Alain Patrick Algazi, Katy K. Tsai, Alexander Noor Shoushtari, Rodrigo Ramella Munhoz, Zeynep Eroglu, Josep Maria Piulats, Patrick Alexander Ott, Douglas Buckner Johnson, Jimmy J. Hwang, ADIL I. DAUD et al. · 2016 · Cancer